Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline


Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

Pivotal Phase 3 clinical trials of antibiotic candidate ceftolozane/tazobactam, being developed to treat certain infections caused by Gram-negative bacteria, have been completed in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI)…


News & Press

31 Mar

FDA Advisory Committee Unanimously Recommends Approval of Cubist’s SIVEXTRO™ (Tedizolid Phosphate) as Treatment for Serious Skin Infections

Cubist Pharmaceuticals, Inc.announced today that the U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Cubist’s investigational antibiotic SIVEXTRO™ (tedizolid phosphate).

Careers at Cubist


Meet Alice

Vice President of Medical Affairs, International

Alice was hired in the fall of 2013 as Vice President of Medical Affairs, International, charged with building Cubist’s Medical…

Investor Center

Cubist Pharmaceuticals Loading…